Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
Summary
Zelluna announced that the Phase II DOVACC trial for the legacy UV1 cancer vaccine failed to meet its primary endpoint. The company says this result closes out the previously planned wrap-up phase for the UV1 program. Zelluna inherited UV1 through its 2025 business combination with Ultimovacs, but now says it is fully focused on its TCR-NK platform and lead candidate ZI-MA4-1. The company expects only minimal remaining close-out costs and no further material spending on UV1.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected